
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CXCR-4 CRISPR Activation Plasmid (h) | sc-400254-ACT | 20 µg | $397.00 | |||
CXCR-4 CRISPR Activation Plasmid (h2) | sc-400254-ACT-2 | 20 µg | $397.00 |
CXCR4 encodes the chemokine receptor CXCR-4, a seven-transmembrane GPCR that binds CXCL12/SDF-1 to regulate chemotaxis, cell positioning, and tissue homing in hematopoietic, immune, and stromal compartments. CXCR-4 signaling engages downstream pathways including Gαi-mediated inhibition of cAMP, PI3K–AKT, MAPK/ERK, PLC–PKC, and calcium flux, integrating cues that influence migration, survival, and adhesion. Dysregulated CXCR4 activity has been implicated in altered leukocyte trafficking, inflammatory microenvironments, and aberrant cell motility programs. These functions make CXCR4 a widely used node for studying receptor-guided migration, niche interactions, and microenvironment-driven phenotypes in human cell models.
CXCR-4 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CXCR4 expression without altering the underlying DNA sequence.
CXCR-4 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CXCR4 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CXCR4 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CXCR-4 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CXCR4 locus and enabling the study of CXCR-4-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CXCR-4 pathway restoration in tumor cells with silenced or reduced CXCR4 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.